Analysis of the efficacy and influencing factors of preoperative P‐SOX neoadjuvant chemotherapy regimen for progressive gastric cancer—construction of a clinical prediction model
Abstract Preoperative neoadjuvant chemotherapy is one of the most common treatments for patients with advanced gastric cancer that cannot be completely removed by surgery. Nab‐paclitaxel is a nano‐formulation of paclitaxel that has been shown to be effective in treating stomach cancer. In addition,...
Main Authors: | Long Feng, Lei Shao, Shuangshuang Sun, Chengwu Zhang, Baojia Cai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-06-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5977 |
Similar Items
-
The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study
by: Chenghai Zhang, et al.
Published: (2022-11-01) -
Neoadjuvant chemotherapy of epirobicin, oxaliplatin, capecitabine regimen in patients with advanced gastric cancer: a two year study
by: Samiei F, et al.
Published: (2012-10-01) -
Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
by: Qi Jiang, et al.
Published: (2023-05-01) -
Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study
by: Xin Wang, et al.
Published: (2022-04-01) -
Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer
by: Xuejun Gan, et al.
Published: (2023-03-01)